High-density lipoprotein metabolism as a therapeutic target for atherosclerosis
暂无分享,去创建一个
E. Braunwald | J. Beckman | D. Baim | S. Goldhaber | K. Baughman | T. Graboys | C. Blatt | A. Eisenhauer | MichaelJ Landzberg | Paula Johnson | Gavin Blake | G. Blake
[1] D. Rader,et al. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. , 2003, The Journal of clinical investigation.
[2] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[3] D. Rader,et al. Characterization of the lipolytic activity of endothelial lipase. , 2002, Journal of lipid research.
[4] A. Zwinderman,et al. Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study , 2002, Circulation.
[5] D. Rader,et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. , 2001, The American journal of cardiology.
[6] M. Hayden,et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. , 2000, The Journal of clinical investigation.
[7] M. Jaye,et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. , 2000, Nature medicine.
[8] D. Rader,et al. High-density lipoprotein metabolism: Molecular targets for new therapies for atherosclerosis , 2000, Current atherosclerosis reports.
[9] A. Callow,et al. Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[10] K. Wakitani,et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.
[11] Bezafibrate Infarction Prevention study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.
[12] J. Mckenney,et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. , 2000, Archives of internal medicine.
[13] D. Rader,et al. Endothelial lipase colon; a new member of the triglyceride lipase gene family , 2000, Current opinion in lipidology.
[14] D. Rader,et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. , 1999, Circulation.
[15] D. Rader,et al. ABC1: connecting yellow tonsils, neuropathy, and very low HDL. , 1999, The Journal of clinical investigation.
[16] P. Barter,et al. Remodelling of high density lipoproteins by plasma factors. , 1999, Atherosclerosis.
[17] P. Connelly,et al. The role of hepatic lipase in lipoprotein metabolism. , 1999, Clinica chimica acta; international journal of clinical chemistry.
[18] Sungshin Y. Choi,et al. Cloning of a Unique Lipase from Endothelial Cells Extends the Lipase Gene Family* , 1999, The Journal of Biological Chemistry.
[19] D. Rader,et al. Role of fibrates in the management of hypertriglyceridemia. , 1999, The American journal of cardiology.
[20] D. Rader,et al. A novel endothelial-derived lipase that modulates HDL metabolism , 1999, Nature Genetics.
[21] A. Goldberg,et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. , 1998, The American journal of cardiology.
[22] D. Capuzzi,et al. Treatment of hyperlipidemia with combined niacin-statin regimens. , 1998, The American journal of cardiology.
[23] H. Suzuki,et al. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. , 1998, Preventive medicine.
[24] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[25] D. Levy,et al. Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.
[26] G. Assmann,et al. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. , 1997, Journal of lipid research.
[27] D. Rader,et al. Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models , 1996, Current opinion in lipidology.
[28] P. Barter,et al. Molecular mechanisms of reverse cholesterol transport , 1996, Current opinion in lipidology.
[29] S. Kihara,et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[30] J. Ordovás,et al. Familial hypoalphalipoproteinemia in premature coronary artery disease. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[31] R. Krauss,et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. , 1993, The Journal of clinical investigation.
[32] A. Tall,et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.
[33] A. Tall. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. , 1990, The Journal of clinical investigation.
[34] V. Fuster,et al. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.
[35] D. Gordon,et al. High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.
[36] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[37] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.